Stockholm, October 3rd, 2018 – After over 8 years as the CEO at ContextVision, Anita Tollstadius has informed the Board of Directors that she wishes to retire during 2019, to spend more time with her family.
“We want to thank Anita for her hard work and contribution to the Company since she became CEO in 2010. She has been instrumental in building an organization, which is uniquely positioned today – compared to our competition – to become a true leader within artificial intelligence based prognostic systems, initially within the field of digital pathology. The Board will now initiate the search process for a new CEO with the aim to secure a smooth succession”, says Erik Danielsen, Chairman of the Board of Directors.
“These eight years have been a fantastic journey together with a great team of colleagues, and the company is certainly facing more exciting times than ever. However, I plan to leave all operative duties during next year in order to spend more time with my family. This seems to me like a good point in time as the company has gone through a major change and is now ready for a new phase. Our present business is very solid and we are on the doorstep to enter into a new market with great potential”, says Anita Tollstadius.
For further information, please contact ContextVision’s CEO, Anita Tollstadius, cell: +46 70 337 30 26 or Erik Danielsen, Chairman of the Board of Directors, cell: + 41 76 335 44 02
About ContextVision
ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence. ContextVision is the global market leader within image enhancement and is a software partner to leading medical imaging manufacturers all over the world. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
As an industry pioneer for more than 30 years, ContextVision is significantly investing in R&D to develop new applications of the latest artificial intelligence technologies and expanding into the growing digital pathology market. The release of its first product, supporting the diagnosis of prostate cancer, is planned in the near future.
The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.
For more information please visit www.contextvision.com